TABLE 1.
Characteristics of persons recruited at the 35‐year follow‐up (n = 320) compared to persons living in study communities that were eligible but who we did not recruit (n = 392), Alaska
| Characteristic | Vax demo 35 cohort (n = 320) % (N) | Persons who were eligible but not recruited (n = 392) % (N) | p value a |
|---|---|---|---|
| Female | 49.4 (158) | 49.2 (193) | 0.97 |
| Mean age at 35‐year follow‐up, years | 48.8 | 49.4 | 0.42 |
| Age group at booster vaccination (age at primary vaccination), years | |||
| <40 (<5) | 13.4 (43) | 14.8 (58) | 0.049 |
| 40 to <45 (5 to <10) | 22.8 (73) | 25.0 (98) | |
| 45 to <55 (10 to <20) | 46.6 (149) | 40.8 (160) | |
| ≥55 (≥20) | 17.2 (55) | 19.4 (76) | |
| Anti‐HBs after primary series group, mIU | |||
| 10–199 | 9.1 (29) | 13.1 (48) | 0.16 |
| 200–499 | 9.7 (31) | 8.2 (30) | |
| 500–999 | 12.5 (40) | 14.5 (53) | |
| ≥1000 | 68.7 (220) | 64.2 (235) | |
| 10‐year anti‐HBs level, mIU | n = 248 | n = 285 | |
| <10 | 10.1 (25) | 18.6 (53) | 0.28 |
| 10–199 | 47.2 (117) | 42.5 (121) | |
| 200–499 | 21.0 (52) | 17.5 (50) | |
| 500–999 | 9.2 (23) | 7.7 (22) | |
| ≥1000 | 12.5 (31) | 13.7 (39) |
a
Female and age group were tested using the likelihood‐ratio chi‐square test. The Cochran‐Armitage trend test was used to analyze anti‐HBs levels after the HBV primary series and 10‐year anti‐HBs level.